Objective To investigate the efficacy of dapagliflozin for overweight/obese patients with type 2 diabetes after 12 weeks of treatment with liraglutide.Methods A total of 93 overweight/obese type 2 diabetes patients who had been treated with liraglutide for just 12 weeks were randomly divided into the liraglutide group (n=46) and the dapagliflozin group (n=47).Patients in the liraglutide group continued to take liraglutide, while the dapagliflozin group switched to dapagliflozin. The treatment lasted 12 weeks in both groups before the changes of blood glucose, weight, waist circumference and blood pressure were compared.Results The blood glucose, weight, waist circumference and blood pressure were significantly lower in both groups after treatment(P<0.01). The extent to which fasting blood glucose [(1.0±0.6)vs(0.8±0.5)] mmol/L, 2-hour postprandial blood glucose[(1.3±0.8)vs(1.4±0.9)] mmol/L, glycated hemoglobin [(1.0±0.5)vs(0.9±0.6)]%, body weight [(1.5±1.4)vs(1.0±1.2)] kg, body mass index[(0.7±0.6)vs(0.5±0.4)] kg/m², systolic blood pressure[(5.0±3.0)vs(5.0±2.5)]mmHg, and diastolic blood pressure[(3.0±1.0)vs(3.0±1.2)]mmHg (P>0.05) decreased was not statistically different between the two groups. However, the waist circumference of the dapagliflozin group decreased less significantly [(1.9±1.3)vs(0.9±0.8)] cm(P<0.01).Conclusions For overweight/obese patients with type 2 diabetes after liraglutide treatment, switching to dapagliflozin will have the same effect as continued treatment with liraglutide on blood glucose, weight, and blood pressure except for the waist circumference.